Cartesian Therapeutics Announces New Employment Inducement Grants
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
BTIG Starts Cartesian Therapeutics (RNAC) at Buy
December 19, 2024 5:55 AM ESTBTIG analyst Julian Harrison initiates coverage on Cartesian Therapeutics (NASDAQ: RNAC) with a Buy rating and a price target of $42.00.
The analyst comments "Cartesian is pioneering the field of mRNA-based CART cell therapies for autoimmune disorders. Many investors were introduced to the broader space earlier in late 2023 / early 2024 following case reports of deep remissions in SLE and MG with DNA-based CD19 CAR-T therapies, but this initial excitement faded... More
